The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia

The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia

Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.

Saved in:
Bibliographic Details
Main Authors: Rego,Thiago Carlos Gonçalves, Massumoto,Celso Mitsushi, Batista,Rodrigo Siqueira, Moura,Larissa Hanauer de, Soares,Lygia Maria Costa, Gomes,Andréia Patrícia
Format: Digital revista
Language:English
Published: Brazilian Society of Infectious Diseases 2007
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000100038
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1413-86702007000100038
record_format ojs
spelling oai:scielo:S1413-867020070001000382007-06-29The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemiaRego,Thiago Carlos GonçalvesMassumoto,Celso MitsushiBatista,Rodrigo SiqueiraMoura,Larissa Hanauer deSoares,Lygia Maria CostaGomes,Andréia Patrícia Anti-CD 20 monoclonal type II mixed cryoglobulinemia hepatitis C Hodgkin's disease Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.info:eu-repo/semantics/openAccessBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious Diseases v.11 n.1 20072007-02-01info:eu-repo/semantics/reporttext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000100038en10.1590/S1413-86702007000100038
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Rego,Thiago Carlos Gonçalves
Massumoto,Celso Mitsushi
Batista,Rodrigo Siqueira
Moura,Larissa Hanauer de
Soares,Lygia Maria Costa
Gomes,Andréia Patrícia
spellingShingle Rego,Thiago Carlos Gonçalves
Massumoto,Celso Mitsushi
Batista,Rodrigo Siqueira
Moura,Larissa Hanauer de
Soares,Lygia Maria Costa
Gomes,Andréia Patrícia
The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
author_facet Rego,Thiago Carlos Gonçalves
Massumoto,Celso Mitsushi
Batista,Rodrigo Siqueira
Moura,Larissa Hanauer de
Soares,Lygia Maria Costa
Gomes,Andréia Patrícia
author_sort Rego,Thiago Carlos Gonçalves
title The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
title_short The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
title_full The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
title_fullStr The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
title_full_unstemmed The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia
title_sort use of monoclonal antibody (rituximab) in the treatment of type ii mixed cryoglobulinemia
description Anti-CD20 monoclonal antibody has been successfully used to treat several self-immune diseases. The authors report the case of a 71 year-old female patient under the use of pegylated form of interferon á associated with ribavirin for the treatment of hepatitis C, who, after concluding the therapeutic program - negative Polymerase Chain Reaction (PCR) - developed a severe cutaneous vasculitis, receiving the diagnostic of type II mixed cryoglobulinemia. Four sessions of plasmapheresis were prescribed along the period of 11 days, with no result. The choice made was to administer anti-CD 20 monoclonal antibody (rituximab), 375 mg/m², per week, during four consecutive weeks. One could observe fast recovery from the purpura, as well as total remission of urticaria.
publisher Brazilian Society of Infectious Diseases
publishDate 2007
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000100038
work_keys_str_mv AT regothiagocarlosgoncalves theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT massumotocelsomitsushi theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT batistarodrigosiqueira theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT mouralarissahanauerde theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT soareslygiamariacosta theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT gomesandreiapatricia theuseofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT regothiagocarlosgoncalves useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT massumotocelsomitsushi useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT batistarodrigosiqueira useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT mouralarissahanauerde useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT soareslygiamariacosta useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
AT gomesandreiapatricia useofmonoclonalantibodyrituximabinthetreatmentoftypeiimixedcryoglobulinemia
_version_ 1756416352973750272

Similar Items